Recursion Pharmaceuticals, Inc.
RXRX
$4.64
$0.317.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.79M | 58.84M | 65.18M | 49.64M | 46.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.79M | 58.84M | 65.18M | 49.64M | 46.24M |
| Cost of Revenue | 432.40M | 359.66M | 327.90M | 322.10M | 303.42M |
| Gross Profit | -372.61M | -300.82M | -262.71M | -272.47M | -257.18M |
| SG&A Expenses | 201.53M | 178.29M | 132.64M | 124.09M | 120.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 633.93M | 537.95M | 460.54M | 446.19M | 423.96M |
| Operating Income | -574.14M | -479.11M | -395.36M | -396.55M | -377.72M |
| Income Before Tax | -575.28M | -464.79M | -382.95M | -380.29M | -358.95M |
| Income Tax Expenses | -507.00K | -1.13M | -5.20M | -5.36M | -4.84M |
| Earnings from Continuing Operations | -574.78 | -463.66 | -377.75 | -374.93 | -354.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -574.78M | -463.66M | -377.75M | -374.93M | -354.11M |
| EBIT | -574.14M | -479.11M | -395.36M | -396.55M | -377.72M |
| EBITDA | -525.69M | -442.62M | -364.26M | -365.08M | -349.67M |
| EPS Basic | -1.78 | -1.66 | -1.55 | -1.64 | -1.62 |
| Normalized Basic EPS | -1.11 | -1.04 | -0.98 | -1.04 | -1.03 |
| EPS Diluted | -1.78 | -1.66 | -1.55 | -1.64 | -1.62 |
| Normalized Diluted EPS | -1.11 | -1.04 | -0.98 | -1.04 | -1.03 |
| Average Basic Shares Outstanding | 1.26B | 1.10B | 983.96M | 915.70M | 874.92M |
| Average Diluted Shares Outstanding | 1.26B | 1.10B | 983.96M | 915.70M | 874.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |